{"id":"obr","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":{"setId":"2ad7837c-b7e0-451c-a9d8-06d3ac146922","title":"OBRILO HAND SANITIZER FORMULATED WITH ALOE (ALCOHOL) GEL [YIWU YANGJIE DAILY CHEMICALS CO.,LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OBR (aripiprazole monohydrate) is a depot formulation of aripiprazole, a partial dopamine D2 receptor agonist. It is administered as a monthly intramuscular injection, providing sustained antipsychotic effects by maintaining therapeutic dopamine antagonism over an extended period, thereby improving medication adherence and reducing relapse rates in psychotic disorders.","oneSentence":"OBR is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to treat schizophrenia and bipolar disorder.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:12:28.088Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (maintenance treatment)"},{"name":"Bipolar I disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT07220772","phase":"PHASE3","title":"A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-02-09","conditions":"Monogenic Obesity","enrollment":4},{"nctId":"NCT07012226","phase":"NA","title":"Comparison of Cardiometabolic Markers in Individuals With Hypertriglyceridemia With Low and High Weight Loss Responses to an Energy-restricted Diet","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-06-10","conditions":"Obesity and Overweight, Hypertriglyceridaemia","enrollment":60},{"nctId":"NCT07302802","phase":"","title":"Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice","status":"RECRUITING","sponsor":"Prof. Dr. Martin Wabitsch","startDate":"2025-12-01","conditions":"Monogenic Obesity","enrollment":70},{"nctId":"NCT06749054","phase":"PHASE2","title":"Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-03-26","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT04159415","phase":"PHASE2","title":"Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-01-07","conditions":"Generalized Lipodystrophy","enrollment":16},{"nctId":"NCT05088460","phase":"PHASE2","title":"A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-02-28","conditions":"Familial Partial Lipodystrophy, Metabolic Abnormalities","enrollment":20},{"nctId":"NCT06548100","phase":"PHASE3","title":"A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-12-16","conditions":"Generalized Lipodystrophy","enrollment":9},{"nctId":"NCT06671756","phase":"NA","title":"Metabolic Effects of Fructose Intake","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2024-12-02","conditions":"Healthy","enrollment":8},{"nctId":"NCT03141060","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-30","conditions":"Tuberculosis, HIV Infections","enrollment":37},{"nctId":"NCT05327803","phase":"PHASE2, PHASE3","title":"Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease","status":"TERMINATED","sponsor":"AN2 Therapeutics, Inc","startDate":"2022-05-20","conditions":"MAC Lung Disease, Treatment Refractory MAC Lung Disease","enrollment":177},{"nctId":"NCT06775990","phase":"","title":"Molecules Associated with Pediatric Obesity","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2020-06-04","conditions":"OBESITY","enrollment":60},{"nctId":"NCT06496308","phase":"PHASE3","title":"Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-07-10","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":78},{"nctId":"NCT05495204","phase":"","title":"External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA","status":"COMPLETED","sponsor":"Epividian","startDate":"2022-08-05","conditions":"HIV-1-infection","enrollment":141},{"nctId":"NCT03013543","phase":"PHASE2","title":"Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity","status":"COMPLETED","sponsor":"Rhythm Pharmaceuticals, Inc.","startDate":"2017-02-10","conditions":"Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency","enrollment":213},{"nctId":"NCT01918397","phase":"PHASE2","title":"Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB","status":"COMPLETED","sponsor":"Boston University","startDate":"2015-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":111},{"nctId":"NCT03287960","phase":"PHASE3","title":"Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity","status":"COMPLETED","sponsor":"Rhythm Pharmaceuticals, Inc.","startDate":"2018-01-30","conditions":"Leptin Receptor Deficiency Obesity","enrollment":15},{"nctId":"NCT04406727","phase":"PHASE3","title":"UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"United BioPharma","startDate":"2023-12-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT00685360","phase":"PHASE2","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-05-08","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis","enrollment":481},{"nctId":"NCT01131351","phase":"PHASE2","title":"Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-02-19","conditions":"Tuberculosis","enrollment":10},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT01504841","phase":"PHASE1, PHASE2","title":"Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-14","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT02573350","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-03-26","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":213},{"nctId":"NCT04892979","phase":"NA","title":"3R Rehabilitation Management of COVID-19 Survivors","status":"UNKNOWN","sponsor":"The Hong Kong Polytechnic University","startDate":"2020-10-01","conditions":"Covid19","enrollment":400},{"nctId":"NCT02707861","phase":"PHASE3","title":"Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2016-03","conditions":"HIV","enrollment":79},{"nctId":"NCT04329260","phase":"","title":"Mutation of the LEPR Gene at Reunion Island: Involvement in Pediatric Obesity","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2021-03","conditions":"Obesity, Childhood","enrollment":250},{"nctId":"NCT01859923","phase":"PHASE2","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-07-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":37},{"nctId":"NCT02475629","phase":"PHASE3","title":"Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2015-08","conditions":"HIV","enrollment":40},{"nctId":"NCT01424670","phase":"PHASE3","title":"Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-09-02","conditions":"Multidrug-resistant Tuberculosis","enrollment":511},{"nctId":"NCT01568892","phase":"PHASE3","title":"Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-04-18","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01856634","phase":"PHASE1","title":"Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-06-14","conditions":"Multidrug Resistant Tuberculosis, Pediatric","enrollment":37},{"nctId":"NCT00583999","phase":"","title":"The Role of Leptin Receptors in NASH","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2006-01","conditions":"Nonalcoholic Steatohepatitis, Metabolic Syndrome","enrollment":104},{"nctId":"NCT00352053","phase":"PHASE3","title":"Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-06","conditions":"HIV Infections","enrollment":87},{"nctId":"NCT00665847","phase":"PHASE2","title":"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-11","conditions":"HIV-1","enrollment":103},{"nctId":"NCT00440271","phase":"PHASE3","title":"SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-02","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT00254046","phase":"PHASE3","title":"TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-11","conditions":"HIV","enrollment":616},{"nctId":"NCT00359021","phase":"PHASE3","title":"An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2006-06","conditions":"HIV-1","enrollment":503},{"nctId":"NCT00255099","phase":"PHASE3","title":"TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-12","conditions":"HIV","enrollment":593},{"nctId":"NCT01026727","phase":"PHASE2","title":"A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy","status":"TERMINATED","sponsor":"Myrexis Inc.","startDate":"2009-11","conditions":"HIV Infections","enrollment":2},{"nctId":"NCT00967187","phase":"PHASE2","title":"Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.","status":"COMPLETED","sponsor":"Myrexis Inc.","startDate":"2008-05","conditions":"HIV Infections","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1023,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"OBR","genericName":"OBR","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OBR is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to treat schizophrenia and bipolar disorder. Used for Schizophrenia (maintenance treatment), Bipolar I disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}